Ingredient: Enoxaparin sodium

　　Efficacy: Enoxaparin sodium can effectively prevent deep vein thrombosis and pulmonary embolism, effectively treat venous thrombosis, prevent thrombosis in extracorporeal blood during hemodialysis, treat unstable angina pectoris and non-Q wave myocardial infarction.

　　Dosage and administration: adults at high risk of DVT were given 40mg at 12 hr before surgery, followed by subcutaneous injection of 40mg every 24hr. Patients at moderate thrombotic risk were given 20mg at 2hr preoperatively, followed by subcutaneous injection every 24 hr. The course should last 10-14 days or until the risk of thrombosis has disappeared. Treatment of venous thrombosis at 1 mg/kg bw, subcutaneous administration every 12 hr for 10 days. Single dose before extracorporeal circulation dialysis: 1mg/kg body weight. The above dose is sufficient for a 4hr dialysis course (unless fibrin rings are formed), and a quarter of the above dose must be added per hour if the dialysis is prolonged. Unstable angina pectoris and non-q-wave myocardial infarction were subcutaneously administered at 1mg/kg body weight every 12 hr within 24hr, lasting for 6-8 days until clinical symptoms stabilized.

　　Contraindications: acute bacterial endocarditis, haemorrhage, thrombocytopenia; Active digestive ulcer, stroke (except for systemic embolism) and bleeding tendency.

　　Adverse reactions: can lead to thrombocytopenia, abnormal liver function. Occasional changes of transaminase and alkaline phosphatase were observed.

　　Note: This drug should not be used for intramuscular injection. Use with caution in patients with hepatic insufficiency, uncontrolled arterial hypertension, history of gastrointestinal ulcer, and pregnant women. Pregnant women should weigh the pros and cons of using this drug.

　　Specification: Injection is mainly divided into: 20 mg x 2 pieces. 40 mg x 2 pieces. 60mg x 2 pieces. 80mg x 2 pieces. 100mg x 2 pieces.